| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4028455 | Ophthalmology | 2008 | 12 Pages |
Abstract
By conventional standards and the most commonly used second-eye and combined models, intravitreal ranibizumab administered for occult/minimally classic subfoveal choroidal neovascularization is a cost-effective therapy. Ranibizumab treatment confers considerably greater value than other neovascular macular degeneration pharmaceutical therapies that have been studied in randomized clinical trials.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Melissa M. MD, MBA, Gary C. MD, MBA, Heidi C. MBA, Jonathan MD, MS,